In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology

Sayaka Deguchi, Tomohiro Shintani, Kazuo Harada, Toru Okamoto, Akinori Takemura, Kazumasa Hirata, Kousei Ito, Kazuo Takayama, Hiroyuki Mizuguchi – 4 May 2021 – In drug development, a system for predicting drug metabolism and drug‐induced toxicity is necessary to ensure drug safety. Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) is an important drug‐metabolizing enzyme expressed in the liver and small intestine, and predicting CYP3A4‐mediated drug metabolism and drug‐induced toxicity is essential.

Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response

Hidenori Toyoda, Atsushi Hiraoka, Haruki Uojima, Akito Nozaki, Noritomo Shimada, Koichi Takaguchi, Hiroshi Abe, Masanori Atsukawa, Kentaro Matsuura, Toru Ishikawa, Shigeru Mikami, Tsunamasa Watanabe, Ei Itobayashi, Kunihiko Tsuji, Taeang Arai, Satoshi Yasuda, Makoto Chuma, Tomonori Senoh, Akemi Tsutsui, Tomomi Okubo, Takuya Ehira, Takashi Kumada, Junko Tanaka – 4 May 2021 – Hepatocellular carcinoma (HCC) can de novo develop in patients with chronic hepatitis C even after the achievement of sustained virologic response (SVR).

Frailty and Sarcopenia in Acute‐on‐Chronic Liver Failure

Lorena Puchades Renau, Julia Herreras López, Maria Àngels Cebrià i Iranzo, Natalia Cezón Serrano, Tommaso Di Maira, Marina Berenguer – 3 May 2021 – In patients with cirrhosis, sarcopenia is a critical reduction in skeletal muscle mass and frailty represents a status of global physical dysfunction caused by under nutrition, muscle wasting, and functional impairment. Both are prevalent conditions in liver transplant candidates and have shown to be independent predictors of adverse outcome.

Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis

Patrick Marquardt, Po‐Hong Liu, Joshua Immergluck, Jocelyn Olivares, Ana Arroyo, Nicole E. Rich, Neehar D. Parikh, Adam C. Yopp, Amit G. Singal – 3 May 2021 – Professional society guidelines recommend semiannual screening for hepatocellular carcinoma (HCC) in patients with cirrhosis; however, studies suggest underuse of screening in clinical practice. Our study’s aim was to characterize reasons for HCC screening underuse among patients with cirrhosis. We conducted a retrospective cohort study of patients with cirrhosis diagnosed with HCC in two large health systems from 2011 to 2019.

Point‐of‐Care Assessment of DCD Livers During Normothermic Machine Perfusion in a Nonhuman Primate Model

Samuel J. Kesseli, Jared N. Gloria, Nader Abraham, Samantha E. Halpern, Greta N. Cywinska, Min Zhang, Dimitrios Moris, Robin Schmitz, Brian I. Shaw, Zachary W. Fitch, Mingqing Song, Cynthia D. Guy, Mathew G Hartwig, Stuart Knechtle, Andrew S. Barbas – 3 May 2021 – Normothermic machine perfusion (NMP) provides clinicians an opportunity to assess marginal livers before transplantation. However, objective criteria and point‐of‐care (POC) biomarkers to predict risk and guide decision making are lacking.

Subscribe to